Tag: urothelial cancer

Second-line single-agent chemotherapies or immune checkpoint inhibitors have provided suboptimal response rates and survival benefits in patients with locally advanced and unresectable or metastatic urothelial carcinoma. Certain types of urothelial carcinomas, such as the luminal I subtype, have higher percentages of mutations in the genes encoding fibroblast growth factor...